美國多發性骨髓瘤治療

Abstract

This report analyzes the US market for Multiple Myeloma Therapeutics in Millions of US$. TThe market for multiple myeloma therapeutics is analyzed by the following Drugs: Thalomid, Revlimid, Velcade, and Others. The market for multiple myeloma therapeutics is also analyzed by the Lines of Treatment - Induction Therapy for SCT Candidates, Induction Therapy for Non-SCT Candidates, and Therapy for Relapsed or Refractory Myeloma. Annual forecasts are provided for the period of 2006 through 2015. The report profiles 98 companies including many key and niche players such as Amgen Inc., Avalon Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Kosan Biosciences, Inc., Celgene Corporation, F. Hoffmann-La Roche Ltd, Genentech, Inc., Genta Incorporated, Millennium Pharmaceuticals, Ortho Biotech Products, LP, Seattle Genetics, and Ziopharm Oncology, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study

II. A US MARKET REPORT

1. Industry Overview

• Hematological Cancer Therapies: A Prelude
• Treatment Regimes: The Golden Rule
• Multiple Myeloma: A Second Most Common Hematological Cancer
• Table 1: Hematological Malignancies in the US (2007): Number of Incidences and Deaths by Type of Cancer - Lymphoma (Hodgkin' s Lymphoma and Non-Hodgkin' s Lymphoma), Multiple Myeloma, Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, and Other Leukemia), and Myelodysplastic Syndromes (MDS) (includes corresponding Graph/Chart)
• Table 2: Blood Cancer Statistics in the US (2008E): Percentage Breakdown of Hematological Cancer Cases by Type: Lymphoma, Myeloma, and Leukemia (includes corresponding Graph/Chart)
• Table 3: Multiple Myeloma Statistics in the US (2008E): Number of Persons Undergoing Initial Diagnosis and Monitoring (includes corresponding Graph/Chart)
• Treatment Therapies: Move Up the Learning Curve
• Risk-Adapted Therapy: The New Norm of Future Treatment
• New Generation Drugs in the Arsenal Against Multiple Myeloma
• Velcade(r) (Bortezomib)
• Thalomid(r) (Thalidomide)
• Revlimid(r) (Lenalidomide)
• Alkeran (Melphalan)
• Doxil (Liposomal Doxorubicin)
• Trisenox(r) (Arsenic trioxide)
• Noteworthy Issues Related to Major Drugs: An Evaluation of Pros and Cons
• Revlimid Overtakes Thalomid: Why?
• How Effective Will Thalomid Be in the 3rd Line Setting? Skepticism Overflows...
• Revlimid Impedes Stem Cell Harvesting!!: What' s the Truth?
• 1st & 2nd Generation Geldanamycin Analog to Do Wonders for Myeloma Treatment
• Other Trends & Issues
• Approval of New Generation Drugs Push the Market Into the Bulge Bracket
• Growth Fundamentals Get Stronger
• Table 4: Key Drug Regimens in the US Multiple Myeloma Market (2006): Breakdown of Typical Length of Treatment Cycle and Cost per Cycle (In US$) (includes corresponding Graph/Chart)
• Multidrug Resistance: A Challenge to Reckon With
• Gene Therapy Exudes Hope
• Challenges Encountered in Clinical Trials
• FDA' s Antidotes
• Europe Lagging Behind in Drug Approvals
• Table 5: Multiple Myeloma Market in Europe (2006): Percentage Breakdown of Drugs Used in First Line Treatment - Melphalan, Thalidomide, Velcade, Doxorubicin, and Others (includes corresponding Graph/Chart)
• Table 6: Multiple Myeloma Market in Europe (2006): Percentage Breakdown of Drugs Used in Second Line Treatment - Melphalan, Thalidomide, Velcade, and Doxorubicin (includes corresponding Graph/Chart)
• Table 7: Multiple Myeloma Market in Europe (2006): Percentage Breakdown of Drugs Used in Third Line Treatment - Melphalan, Thalidomide, Velcade, Doxorubicin, and Others (includes corresponding Graph/Chart)
• Market Share Statistics
• Present Batting Order
• Table 8: US Market for Multiple Myeloma Therapeutics (2006): Percentage Breakdown of Revenues by Company - Celgene Corporation, Millennium Pharmaceuticals, Ortho-Biotech, and Others (includes corresponding Graph/Chart)
• Looking Through the Crystal Ball: Year 2013
• Table 9: US Market for Multiple Myeloma Therapeutics (2013P): Percentage Breakdown of Revenues by Company - Celgene Corporation, Millennium Pharmaceuticals Inc, Kosan Biosciences, Ortho Biotech, Ziopharm Oncology Inc and Others (includes corresponding Graph/Chart)
• Oncology and Hematology Market
• Table 10: Leading Players in the Oncology and Hematology Market in the US (2008E): Percentage Breakdown of Value Sales by Company - Amgen, Roche, Novartis, DNA, AstraZeneca, and Others (includes corresponding Graph/Chart)
• Drugs Approved & In Pipeline: A Review
• Multiple Myeloma Drugs Approved by the FDA As of the Year 2008
• Multiple Myeloma Drugs in Pipeline in the US As of the Year 2008
• Phase III Drugs in Pipeline
• Phase II Drugs in Pipeline
• Phase I Drugs in Pipeline
• Key Non-Profit Organizations in the US
• Multiple Myeloma Research Foundation (MMRF)
• National Coalition for Cancer Survivorship (NCCS)
• National Marrow Donor Program (NMDP)
• Oregon Health and Science University Cancer Institute

2. Disease & Treatment Overview

• Cancer: A Definition
• Hematological Cancers
• Types of Hematological Cancer
• Multiple Myeloma
• Multiple Myeloma Stages
• Stage I
• Stage II/III
• Treatment Procedures
• Diagnosis
• Treatment
• Initial Treatment Regimen
• Induction Therapy for SCT Candidates
• Induction Therapy for Non-SCT Candidates
• Therapy for Relapsed or Refractory Myeloma
• Maintenance Therapy for Relapsed or Refractory Myeloma
• Treatment Pros & Cons
• Others Types of Hematological Cancers
• Leukemia
• Acute Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Lymphoma
• Non-Hodgkin' s Lymphoma
• Hodgkin' s Lymphoma
• Myelodysplastic Syndromes
• Hematological Cancer Therapies
• Chemotherapy
• Radiation Therapy
• Stem Cell Transplants
• Biological Therapy
• Targeted Therapy
• Gene Therapy
• Immunotherapy
• Monoclonal Antibody Treatment
• Vaccines
• Donor Lymphocyte Infusion
• Hematological Cancer Drug Classes
• Hypomethylating Agents & Antimetabolites
• Bisphosphonates
• Alkylating Agents and DNA-Damaging Agents
• DNA-Repair Enzyme Inhibitors
• Histone Deacetylase Inhibitor
• Immunomodulators
• Proteasome Inhibitor
• Tyrosine Kinase Inhibitors

3. Clinical Trials and Drug Approvals

• NICE Grants Approval for Use of Revlimid(r)
• SWOG Announces Closure of Phase III Trial (S0232) for Paitents with Multiple Myeloma
• Fujimoto Pharmaceutical Receives Approval to Market Thalidomide
• Celgene Obtains Health Canada Approval for Revlimid Oral Cancer Drug
• FDA Grants Orphan-Drug Designation to Melphalan
• Merck Commences Phase II-b and Phase III Clinical Trial of Zolinza
• Clavis Initiates Phase II Trial of Elacytarabine
• Gilead Sciences Commences GS 9219 Phase I Clinical Trial
• AstraZeneca Carries Out AZD 0530 Phase II trial
• European Commission Grants Approval of Thalidomide for Multiple Myeloma
• EMEA Issues Positive Opinion for Thalidomide Use in Multiple Myeloma
• Global Regulatory Developments for the Use of Revlimid(r) in Multiple Myeloma
• Takeda Gains FDA Approval to Promote Velcade
• Health Canada Approves VELCADE
• Genzyme Receives FDA Certification for Mozobil
• Celgene' s Thalidomide Pharmion Receives Marketing Authorization
• Ziopharm Commences Phase II Clinical Trial of ZIO-101
• FDA Approves Pluristem' s Pre-IND Application of PLX-I
• Merck Pharmaceuticals Commences Phase I Study for R763 Kinase Inhibitor
• Swissmedic Approves Celgene' s REVLIMID Oral Cancer Drug
• Celgene' s REVLIMID Receives EU' s Marketing Authorization
• FDA Approves Application of Piramal' s IND-P276 Multiple Myeloma Drug
• Millennium Pharmaceuticals and Johnson & Johnson Initiate Velcade(r) Phase II Trial
• FDA to Consider the New Drug Application Filed for Use of Doxil(r) Combined with Velcade(r) in Patients with Multiple Myeloma
• Ortho Biotech Files Application with FDA for Approval of Combination Drug DOXIL(r) and VELCADE(r)
• Caraco' s Allopurinol Receives FDA Approval
• FDA Approves Thalomid(r) as Combination Therapy for Multiple Myeloma
• Revlimid(r) Obtains Regulatory Approval for the Treatment of Multiple Myeloma
• LymphoSign Inc. Announces Successful Completion of LS104 Drug' s Pre-Clinical Testing
• Seattle Genetics Commences SGN-40 Phase I Clinical Trial
• FDA Approves Use of Revlimid(r) for Multiple Myeloma
• US FDA Approves Use of Thalidomide for Multiple Myeloma
• Ziopharm Oncology Receives Approval to Commence ZIO-101 and ZIO-201 Trial
• FDA Grants Approval for Use of VELCADE(r) for Patients with Mantle Cell Lymphoma

4. Recent Industry Activity

• CytRx to Acquire Innovive
• Launch of Epoetin alfa Hexal
• PDL and Bristol-Myers Signs Agreement
• MNKD and LLS Conclude Joint Research Agreement
• MorphoSys and DSM Enter into Agreement
• StemCyte Enters into Joint Venture with Cadila and Apollo Hospitals in India
• ImmunoCellular Acquires Molecular Antibody Technology
• US House of Representatives Sanction the Hematological Cancer Research Investment and Education Act
• Bayer and Cell Therapeutics Enter into Mutual Agreement
• Bristol-Myers to Take Over Kosan Biosciences
• Bristol and PDL BioPharma Enter into Agreement
• Gamida Cell Enters Into a Agreement with Amgen
• Circadian Acquires Complete Stake in Vegenics
• Takeda Acquires Millennium Pharmaceuticals
• GlaxoSmithKline Forms Alliance with OncoMed for Developing Cancer Therapeutics
• Cyclacel Signs Agreement to Acquire ALIGN Pharmaceuticals
• Biogen and Genentech to Jointly Develop and Commercialize New Blood Cancer Drug
• Aegera Therapeutics Acquires LymphoSign Inc
• Velcade Gains Subsidy
• Inex Pharmaceuticals Spins Off Biotechnology Business into Tekmira Pharmaceuticals
• MilleGen Enters into Collaboration with LFB
• Access Pharmaceuticals to Acquire Somanta
• TopoTarget to Acquire Apoxis SA
• Genentech Inks Exclusive Global Licensing Agreement with Seattle Genetics
• Celgene Agrees to Acquisition of Pharmion
• PerkinElmer Plans Acquisition of ViaCell
• Favrille Announces Acquisition of Monoclonal Antibody Range from Diversa
• Johnson & Johnson Secures Contract worth US$112 Million
• Bioniche Pharma to Acquire Branded Pharmaceutical from Nabi Biopharmaceuticals
• Takara Bio' s RetroNect Used for Clinical Trials of Gene Therapy in Australia
• Millennium Pharmaceuticals to Take Over AnorMED
• MDS Pharma Services Becomes Recommended CRO for Multiple Myeloma Drug R&D
• Celgene Certifies McKesson Specialty to Launch Revlimid
• Medarex and PacMab to Co-Develop Blood Cancer Therapies
• Gamida Cell and Teva to Co-Develop Therapy for Hematological Malignancies
• GlaxoSmithKline to Take Over Praecis Pharmaceuticals
• Biotest Acquires ImmunoGen Anticancer Technology Rights
• Hana Signs Licensing Agreement with Inex
• Cephalon Acquires Zeneus

5. Focus on Select Players

• Amgen Inc (USA)
• Avalon Pharmaceuticals, Inc. (USA)
• Bristol-Myers Squibb Company (USA)
• Kosan Biosciences, Inc. (USA)
• Celgene Corporation (USA)
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Genentech, Inc. (USA)
  • Genta Incorporated (USA)
  • Millennium Pharmaceuticals (USA)
  • Ortho Biotech Products, LP (USA)
  • Seattle Genetics (USA)
  • Ziopharm Oncology, Inc. (USA)

6. Market Perspective

• Table 11: US Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Drug - Thalomid, Revlimid, Velcade, and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 12: US 10-Year Perspective for Multiple Myeloma Therapeutics by Drug - Percentage Breakdown of Dollar Sales for Thalomid, Revlimid, Velcade, and Others for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
• Table 13: US Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Line of Treatment - Induction Therapy for SCT Candidates, Induction Therapy for Non-SCT Candidates, and Therapy for Relapsed or Refractory Myeloma Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 14: US 10-Year Perspective for Multiple Myeloma Therapeutics by Line of Treatment - Percentage Breakdown of Dollar Sales for Induction Therapy for SCT Candidates, Induction Therapy for Non-SCT Candidates, and Therapy for Relapsed or Refractory Myeloma for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE